Patients must not have Common Terminology Criteria for Adverse Events (CTCAE) >= grade  neuropathy (cranial, motor or sensory) within  days prior to registration
Has sensory or motor neuropathy of >= National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) Grade .
Neurologic function: neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 
Neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 
Peripheral sensory neuropathy or peripheral motor neuropathy >= grade  per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) .
Neuropathy (sensory and motor) =< Common Terminology Criteria for Adverse Events (CTCAE) grade 
Pre-existing motor or sensory neurotoxicity greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 
Subjects being enrolled to receive paclitaxel plus carboplatin treatment must have neuropathic function (sensory and motor less than or equal to Grade  according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v. ()
Neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) version . (v.) grade  acceptable
Neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 
Neuropathy (sensory) =< Common Terminology Criteria for Adverse Events (CTCAE) grade 
Neuropathy (sensory and motor) =< grade  according to Common Toxicity Criteria for Adverse Events version  (CTCAE)
Patients with pre-existing neuropathy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade  (motor or sensory)
Sensory or motor neuropathy of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade >=.
